Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Race Oncology Ltd. ( (AU:RAC) ) has shared an update.
Race Oncology Ltd announced that all resolutions at its Annual General Meeting were passed, reflecting strong shareholder support. This outcome may bolster the company’s strategic initiatives in advancing its clinical programs and exploring partnerships, potentially impacting its market position positively.
More about Race Oncology Ltd.
Race Oncology (ASX: RAC) is a biopharmaceutical company focused on cancer care, listed on the Australian Securities Exchange. Their lead product, RCDS1, is an anticancer agent targeting cancer growth regulators, with ongoing clinical programs in various oncology indications. The company collaborates with several institutions and is exploring partnerships to enhance patient access to their treatments.
Average Trading Volume: 546,429
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$514.5M
See more data about RAC stock on TipRanks’ Stock Analysis page.